Published in Lancet on June 19, 1993
Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies. Eur J Clin Microbiol Infect Dis (2006) 0.88
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol (2005) 1.70
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J (1985) 1.48
No serological evidence for non-sexual spread of HPV16. Lancet (1994) 1.47
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42
An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology (2004) 1.40
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer (1985) 1.38
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol (1999) 1.26
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol (2001) 1.23
A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol (2000) 1.23
Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol (2001) 1.20
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer (2002) 1.20
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol (1999) 1.16
Identification of human papillomavirus seroconversions. J Gen Virol (1995) 1.14
Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology (1998) 1.13
Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst (1999) 1.11
Lymphoblastoid cell lines and Burkitt-lymphoma-derived cell lines differ in the expression of a second Epstein-Barr virus encoded nuclear antigen. Int J Cancer (1986) 1.10
Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol (1996) 1.09
Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study. Cancer Causes Control (1993) 1.07
Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev (2000) 1.06
Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer (2000) 1.06
A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res (1997) 1.05
Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology (1995) 1.05
Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer (1998) 1.04
Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer (1987) 1.03
Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol (1991) 1.03
A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer (1996) 1.03
Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis (1996) 1.03
Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev (2000) 1.02
Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains. Nucleic Acids Res (1991) 1.01
The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J Gen Virol (1995) 1.00
Combined effect of low-penetrant SNPs on breast cancer risk. Br J Cancer (2011) 1.00
Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med (1997) 0.99
Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol (2007) 0.99
A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol (2000) 0.98
Nuclear DNA-binding proteins determined by the Epstein-Barr virus-related simian lymphotropic herpesviruses H. gorilla, H. pan, H. pongo and H. papio. J Gen Virol (1987) 0.97
No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer (1999) 0.97
Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J Virol (1991) 0.96
The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol (2009) 0.95
Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer (2003) 0.95
Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer (1990) 0.94
A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer (1999) 0.94
The Epstein-Barr virus determined nuclear antigen is composed of at least three different antigens. Int J Cancer (1986) 0.92
Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer (1999) 0.92
Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer (2004) 0.91
Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis (2000) 0.91
Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol (1995) 0.91
A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. Tissue Antigens (2005) 0.89
Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex Transm Infect (1998) 0.89
Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma. Int J Cancer (1993) 0.89
Immunity to oncogenic human papillomaviruses. Adv Cancer Res (2001) 0.89
Introduction of human papillomavirus (HPV) vaccination in Sweden. Euro Surveill (2009) 0.88
Human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. J Infect Dis (1999) 0.88
Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol (2000) 0.88
Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem (1993) 0.88
A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. Am J Obstet Gynecol (1998) 0.87
Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol (1999) 0.87
Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Cancer Epidemiol Biomarkers Prev (1997) 0.87
Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer (1996) 0.87
A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas. Br J Cancer (2002) 0.87
Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer. Hum Immunol (2001) 0.86
Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. J Med Virol (1995) 0.85
Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies. Oncogene (1994) 0.84
Herpes simplex virus and human papillomavirus in a population-based case-control study of cervical intraepithelial neoplasia grade II-III. APMIS (1998) 0.84
HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int Immunol (1995) 0.84
Levels of immunoglobulin G antibodies against defined epitopes of the L1 and L2 capsid proteins of human papillomavirus type 6 are elevated in men with a history of condylomata acuminata. J Clin Microbiol (1992) 0.84
Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. Br J Cancer (2013) 0.83
Characterization of the complete genomes of Camelus dromedarius papillomavirus types 1 and 2. J Gen Virol (2011) 0.83
Seroepidemiology as basis for design of a human papillomavirus vaccination program. Vaccine (2008) 0.83
Molecular size variation of EBNA is determined by the EB viral genome. Intervirology (1984) 0.82
Preventive human papillomavirus vaccination. Sex Transm Infect (2002) 0.82
A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions. Viral Immunol (1994) 0.82
No evidence of enteroviruses in the intestine of patients with type 1 diabetes. Diabetologia (2012) 0.82
Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J Clin Microbiol (1996) 0.82
A population-based case-control study of human papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix. Int J Cancer (1996) 0.81
Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. J Gen Virol (1997) 0.81
A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA. Clin Diagn Lab Immunol (1994) 0.81
Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia. Br J Cancer (2010) 0.81